Seaport Therapeutics, Inc. (SPTX) Cash Flow Statement
Where SPTX’s cash came from and went, 2025
December 31, 2025 · U.S. dollars- Cash from operations
- −$77.9M
- Capital expenditures
- $356,000
- Free cash flow
- −$78.3M
- Returned to shareholders
- —
- Change in cash
- −$263.1M cash at year-end $46.5M
Drawn to scale: where the cash came from and how it was used. Hover for values.
SPTX operating cash flow, capex and free cash flow
SPTX cash flow trends, 2024–2025
| Metric | Trend | Then | Latest | Change |
|---|---|---|---|---|
| Operating cash flow | −$29.6M2024 | −$77.9M2025 | — | |
| Capital expenditures | $113,0002024 | $356,0002025 | +215.0%/yr | |
| Free cash flow | −$29.7M2024 | −$78.3M2025 | — | |
| Stock-based compensation | $14.5M2024 | $6.9M2025 | −52.6%/yr |
Change is the average annual growth (CAGR) or the difference between the first and latest year.
SPTX cash flow by activity
SPTX net income vs operating cash flow
Operating cash flow above net income usually means earnings are backed by cash (depreciation and stock-based pay are non-cash expenses).
SPTX cash flow statement
| 2025 | 2024 | |
|---|---|---|
| Operating activities | ||
| Net income | −$74.9M | −$46.9M |
| Depreciation & amortization | $1.4M | $214,000 |
| Stock-based compensation | $6.9M | $14.5M |
| Change in working capital | −$7.9M | $2.5M |
| Other non-cash items | −$3.4M | $0 |
| Cash from operating activities | −$77.9M | −$29.6M |
| Investing activities | ||
| Capital expenditures | −$356,000 | −$113,000 |
| Investments (net) | −$183.9M | $0 |
| Acquisitions & other investing | $0 | — |
| Cash from investing activities | −$184.2M | — |
| Financing activities | ||
| Shares issued | $0 | $326.1M |
| Other financing | −$873,000 | $13.2M |
| Cash from financing activities | −$873,000 | $339.3M |
| Summary | ||
| Net change in cash | −$263.1M | $309.6M |
| Cash at end of period | $46.5M | $309.6M |
| Free cash flow | −$78.3M | −$29.7M |
| Jun '26 | Mar '26 | Mar '25 | |
|---|---|---|---|
| Operating activities | |||
| Net income | −$62.6M | −$25.4M | −$13.1M |
| Depreciation & amortization | $351,000 | $357,000 | $315,000 |
| Stock-based compensation | — | $2.6M | $1.6M |
| Change in working capital | −$396,000 | $2.5M | −$8.2M |
| Other non-cash items | $36.5M | −$223,000 | −$835,000 |
| Cash from operating activities | −$26.1M | −$20.2M | −$20.2M |
| Investing activities | |||
| Capital expenditures | $0 | $0 | −$54,000 |
| Investments (net) | — | $27.9M | −$225.5M |
| Acquisitions & other investing | −$203.5M | $0 | — |
| Cash from investing activities | −$203.5M | $27.9M | — |
| Financing activities | |||
| Shares issued | $0 | $0 | $0 |
| Other financing | $240.9M | −$783,000 | $0 |
| Cash from financing activities | $240.9M | −$783,000 | $0 |
| Summary | |||
| Net change in cash | $11.3M | $6.9M | −$245.8M |
| Cash at end of period | $64.2M | $53.4M | $63.8M |
| Free cash flow | −$26.1M | −$20.2M | −$20.3M |
Negative numbers are cash paid out. Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported; data from EODHD.
SPTX cash generation
In fiscal 2025 (ended December 31, 2025), Seaport Therapeutics generated -$77.9 million of cash from operations and spent $0.4 million on capital expenditures, leaving free cash flow of -$78.3 million. Cash and equivalents fell by $263.1 million over the year.
Related: SPTX income statement, SPTX balance sheet. See the SPTX stock overview for the latest quote and news.
SPTX cash flow FAQ
What is Seaport Therapeutics's free cash flow?
Seaport Therapeutics's free cash flow was -$78.3 million in fiscal 2025: -$77.9 million of operating cash flow minus $0.4 million of capital expenditures It was -$29.7 million a year earlier..
How much cash does Seaport Therapeutics generate from operations?
Seaport Therapeutics generated -$77.9 million of cash from operating activities in fiscal 2025.
How much does Seaport Therapeutics spend on capital expenditures?
Seaport Therapeutics spent $0.4 million on capital expenditures in fiscal 2025, compared with $0.1 million the year before.